A Phase 1b/2 Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination with other Anti-cancer Agents in Patients with HER2-p
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
AstraZeneca Pharmaceuticals, LP
Start Date
August 16, 2022
End Date
July 9, 2027
Administered By
Duke Cancer Institute
Awarded By
AstraZeneca Pharmaceuticals, LP
Start Date
August 16, 2022
End Date
July 9, 2027